In this MRFR market note, the Chronic Kidney Disease Market is discussed at length that contains the information till 2023, Market Research Future (MRFR) forecasts a CAGR of 6.32% for the Global Renal Disease Market from 2018 to 2023. The market growth is linked to the rising prevalence of diabetes, hypertension, and kidney diseases. According to a report published by the National Kidney Foundation in 2015, about 10% of the total worldwide population is affected by chronic kidney disease.
Players that leading the Market Are
Abbott (US), Amgen Inc. (US), AstraZeneca (US), Bristol-Myers Squibb Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Fresenius Medical Care AG & Co. KGaA (UK), GlaxoSmithKline PLC (UK), Keryx Biopharmaceuticals, Inc (US), Kissei Pharmaceutical Co., Ltd (Japan), Novartis AG (Switzerland), Pfizer Inc. (US), Sanofi SA (France), and Teva Pharmaceutical Industries Ltd (Israel).
Free sample Copy Is Available Here @
Chronic kidney disease will remain the largest disease type in the global renal disease market
The chronic kidney disease segment accounted for a market value of USD 60,228.68 million in 2017. The rising prevalence of chronic kidney disease is expected to drive the growth of the market.
The global renal disease market is expected to register a CAGR of 6.32% during the forecast period with a market value of USD 93,375.70 million in 2017. Renal diseases can be classified as chronic kidney disease (CKD) and end-stage renal disease (ESRD). Renal diseases may cause kidney failure. When CKD worsens, it eventually leads to ESRD. As per the National Institute of Diabetes and Digestive and Kidney Disease Report 2015, more than 6,61,000 Americans had kidney failure.
This huge population suffering from the chronic kidney is expected to boost the renal disease market. Also, rising geriatric population is anticipated to drive the market growth. Currently, the market is dominated by many market players. The growing competition among existing and new market players to develop better renal diseases based products is expected to fuel market growth. Also, key companies are being involved in new product approvals to enhance their market share. For instance, in March 2018, Amgen received the US Food and Drug Administration (FDA) approval for Sensipar, which is an innovative, first in class treatment for a serious complication of chronic kidney disease.
- Pharmaceutical companies
- Contract research manufacturing organizations
- Research & development organizations
- Academic institutes
The global renal disease market, by disease type, has been segmented into chronic kidney disease and end-stage renal diseases (ESRD). The chronic kidney disease segment accounted for a value of USD 60,228.68 million in 2017. The market, by treatment type, can be segmented into dialysis, medications and kidney transplantation. On the basis of end user, the global renal disease market is segmented into dialysis centers, hospitals & clinics, and research and academic institutes.
Medication segment will register the fastest growth in the treatment type segment of the global renal disease market
The medication segment is expected to register a higher CAGR of 7.37% during the forecast period. Growing demand for medications for the primary treatment of renal diseases is expected to drive the market growth.
The dialysis centers segment would dominate the end-user segment in the global renal disease market
The dialysis centers segment accounted for a value of USD 31,737.35 million in 2017. The rising number of dialysis patients is anticipated to boost the market growth of dialysis centers during the assessment period.
Asia-Pacific renal disease market to exhibit the highest CAGR
Asia-Pacific is the fastest-growing market with a CAGR of 7.73% for renal diseases. Australia held a share of 11.8% in the Asia-Pacific renal disease market in 2017. Developing regions such as China, India, and Australia have evolved as major destinations for the outsourcing of clinical trials, drug manufacturing, and pathology testing. Also, the Asia-Pacific region has a large patient pool which creates opportunities for major players to develop treatments and grow in the market.
Browse Research Report Enabled with Respective Tables and Figures @
Table of content
1 Executive Summary
2 Market Introduction
2.1 Scope Of Study
2.2 Research Objective
2.3 List Of Assumptions
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
4 Market Dynamics
4.2.1 Rising Prevalence Of Kidney Disease
4.2.1 Growing Prevalence Of Diabetes And Hypertension
4.2.2 Rapid Growth In The Geriatric Population
4.3.1 Rising Healthcare Cost
4.3.2 Stringent Regulatory Policies
4.4.1 Expansion In Developing Economies
4.5 Market Trends
4.5.1 Artificial Intelligence (AI) For Managing And Diagnosis Of Chronic Kidney Disease (CKD)
4.6 Macroeconomic Indicators
Browse other healthcare-related reports
Oral Thin Film Drugs Market – Global Forecast 2023
by Product (Fast Dissolving Buccal Film, Sublingual), by Disease Indication (Opioid Dependence, Nausea & Vomiting, Schizophrenia, Migraine), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Drug Stores), and Region
Needle-Free Injection Market – Global Forecast 2023
By Product (Fillable) Technology (Jet-Based) Usability (Reusable), Type of Medication (Liquid-Based), Site of Delivery (Intra dermal), Application (Vaccination) End Users (Hospitals)
About Market Research Future:
MRFR team has supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country-level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with the technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Market Research Future
+1 646 845 9312